Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Jakub Neradil"'
Autor:
Karolina Borankova, Maria Krchniakova, Lionel Y. W. Leck, Adela Kubistova, Jakub Neradil, Patric J. Jansson, Michael D. Hogarty, Jan Skoda
Publikováno v:
Cell Death and Disease, Vol 14, Iss 11, Pp 1-17 (2023)
Abstract Mitochondria are central for cancer responses to therapy-induced stress signals. Refractory tumors often show attenuated sensitivity to apoptotic signaling, yet clinically relevant molecular actors to target mitochondria-mediated resistance
Externí odkaz:
https://doaj.org/article/41eadf257f734648918b7150a9589f88
Autor:
Polina Kameneva, Victoria I. Melnikova, Maria Eleni Kastriti, Anastasia Kurtova, Emil Kryukov, Aliia Murtazina, Louis Faure, Irina Poverennaya, Artem V. Artemov, Tatiana S. Kalinina, Nikita V. Kudryashov, Michael Bader, Jan Skoda, Petr Chlapek, Lucie Curylova, Lukas Sourada, Jakub Neradil, Marketa Tesarova, Massimo Pasqualetti, Patricia Gaspar, Vasily D. Yakushov, Boris I. Sheftel, Tomas Zikmund, Jozef Kaiser, Kaj Fried, Natalia Alenina, Elena E. Voronezhskaya, Igor Adameyko
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-21 (2022)
Adrenal glands are major organs regulating stress response., Melnikova et al., show that local release of serotonin limits adrenalin-producing cell number during rodent development, a mechanism which has implications for neuroblastoma development and
Externí odkaz:
https://doaj.org/article/ca903ec136424382bd20c84f80eea462
Autor:
Maria Krchniakova, Silvia Paukovcekova, Petr Chlapek, Jakub Neradil, Jan Skoda, Renata Veselska
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Tyrosine kinase inhibitors (TKIs) are frequently used in combined therapy to enhance treatment efficacy and overcome drug resistance. The present study analyzed the effects of three inhibitors, sunitinib, gefitinib, and lapatinib, combined with iron-
Externí odkaz:
https://doaj.org/article/953b01435918483ea1b53ad2f28c8d72
Autor:
Silvia Paukovcekova, Maria Krchniakova, Petr Chlapek, Jakub Neradil, Jan Skoda, Renata Veselska
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8549 (2022)
Anticancer therapy by anthracyclines often leads to the development of multidrug resistance (MDR), with subsequent treatment failure. Thiosemicarbazones have been previously suggested as suitable anthracycline partners due to their ability to overcom
Externí odkaz:
https://doaj.org/article/cd0f2fcf973e486fa0b9fac94da67dfd
Autor:
Kristyna Polaskova, Tomas Merta, Alexandra Martincekova, Danica Zapletalova, Michal Kyr, Pavel Mazanek, Zdenka Krenova, Peter Mudry, Marta Jezova, Jiri Tuma, Jarmila Skotakova, Ivana Cervinkova, Dalibor Valik, Lenka Zdrazilova-Dubska, Hana Noskova, Karol Pal, Ondrej Slaby, Pavel Fabian, Sarka Kozakova, Jakub Neradil, Renata Veselska, Veronika Kanderova, Ondrej Hrusak, Tomas Freiberger, Giannoula Lakka Klement, Jaroslav Sterba
Publikováno v:
Frontiers in Oncology, Vol 9 (2020)
In order to identify reasons for treatment failures when using targeted therapies, we have analyzed the comprehensive molecular profiles of three relapsed, poor-prognosis Burkitt lymphoma cases. All three cases had resembling clinical presentation an
Externí odkaz:
https://doaj.org/article/5c281799cb3e41e29ab698bc35a5380e
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 1, p 376 (2021)
Despite constant advances in the field of pediatric oncology, the survival rate of high-risk neuroblastoma patients remains poor. The molecular and genetic features of neuroblastoma, such as MYCN amplification and stemness status, have established th
Externí odkaz:
https://doaj.org/article/efd5948838e3485b8f153bf34cf94e6e
Autor:
Michal Mahdal, Jakub Neradil, Peter Mudry, Silvia Paukovcekova, Iva Staniczkova Zambo, Jiri Urban, Peter Macsek, Lukas Pazourek, Tomas Tomas, Renata Veselska
Publikováno v:
Cancers, Vol 13, Iss 14, p 3543 (2021)
Giant-cell tumor of bone (GCTB) is an intermediate type of primary bone tumor characterized by locally aggressive growth with metastatic potential. The aim of this study was to identify new druggable targets among the cell signaling molecules involve
Externí odkaz:
https://doaj.org/article/0359ddf0f0ab42c5a01569643702929b
Autor:
Jakub Neradil, Michal Kyr, Kristyna Polaskova, Leos Kren, Petra Macigova, Jan Skoda, Jaroslav Sterba, Renata Veselska
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The specific targeting of signal transduction by low-molecular-weight inhibitors or monoclonal antibodies represents a very promising personalized treatment strategy in pediatric oncology. In this study, we present the successful and clinically relev
Externí odkaz:
https://doaj.org/article/1c0111a9499a459bb2c611ad6acb8995
Autor:
Michal Kyr, Kristyna Polaskova, Zuzana Kuttnerova, Tomas Merta, Jakub Neradil, Jitka Berkovcova, Ondrej Horky, Marta Jezova, Renata Veselska, Giannoula Lakka Klement, Dalibor Valik, Jaroslav Sterba
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Introduction: The individualization of treatment is attractive, especially in children with high-risk cancer. In such a rare and very heterogeneous group of diseases, large population-based clinical randomized trials are not feasible without internat
Externí odkaz:
https://doaj.org/article/86696cb98eda4de6be30002db1ea2e5d
Autor:
Silvia Paukovcekova, Jan Skoda, Jakub Neradil, Erika Mikulenkova, Petr Chlapek, Jaroslav Sterba, Des R. Richardson, Renata Veselska
Publikováno v:
Cancers, Vol 12, Iss 12, p 3781 (2020)
Combining low-dose chemotherapies is a strategy for designing less toxic and more potent childhood cancer treatments. We examined the effects of combining the novel thiosemicarbazones, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC
Externí odkaz:
https://doaj.org/article/dd6a5bec3acd4bc79a5596913527b6d0